Adding dapagliflozin to metformin therapy enhanced the treatment's efficacy in lowering blood glucose levels in patients newly diagnosed with type 2 diabetes, experts reported at the annual meeting of the American Diabetes Association. One study found that about 52% of patients on metformin-dapagliflozin treatment had hemoglobin A1c levels of 7% or less compared to 34.6% and 22.5% in those who only took either metformin or dapagliflozin, respectively. A second study had similar results.

Related Summaries